Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed adenocarcinoma of the prostate
• * Stage I or II (T1-T2 a, b, or c) disease
• * Disease confined to the prostate by clinical judgment of the surgeon
• Deemed an appropriate candidate for surgery by clinical judgment of the surgeon
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 8.0 g/dL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase ≤ 4 times ULN if AST and/or ALT normal
• Serum creatinine ≤ 2.0 mg/dL
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to oral microencapsulated diindolylmethane
• No concurrent uncontrolled illness including, but not limited to, any of the following:
• * Ongoing or active infection
• * Symptomatic congestive hart failure
• * Unstable angina pectoris
• * Cardiac arrhythmia
• * Psychiatric illness or social situation that would limit compliance with study requirements
• PRIOR CONCURRENT THERAPY:
• No prior chemotherapy, hormonal therapy, brachytherapy, cryotherapy, external beam radiotherapy, or other therapy for prostate cancer
• No concurrent micronutrient supplements or dietary soy products
• No concurrent systemic therapy for any other cancer
• No concurrent p450 inducers or inhibitors (e.g., carbamazepine, clarithromycin, fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin, rifabutin, or rifampin)
• No concurrent finasteride or dutasteride
• No other concurrent investigational or commercial agents or therapies for the malignancy